MedTrace Logo

Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2

NCT01443338 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2011-09-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether Triptergium wilfordii, and Acitretin are effective and safe in the treatment of patient of moderate to severe psoriasis vulgaris.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Triptergium Wilfordii

Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks

DRUG

Acitretin

Capsule,10mg/Cap,30mg Qd,no more than 8 weeks

Sponsors & Collaborators

  • Ministry of Health, China

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01443338 on ClinicalTrials.gov